Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
Advertisement
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Signal Transduction

Activation of Protein Kinase C-ζ by Insulin and Phosphatidylinositol-3,4,5-(PO4)3 Is Defective in Muscle in Type 2 Diabetes and Impaired Glucose Tolerance

Amelioration by Rosiglitazone and Exercise

  1. Mary Beeson1,
  2. Mini P. Sajan1,
  3. Michelle Dizon12,
  4. Dmitry Grebenev12,
  5. Joaquin Gomez-Daspet12,
  6. Atsushi Miura12,
  7. Yoshinori Kanoh12,
  8. Jennifer Powe12,
  9. Gautam Bandyopadhyay12,
  10. Mary L. Standaert12 and
  11. Robert V. Farese12
  1. 1Department of Internal Medicine, Division of Endocrinology and Metabolism, University of South Florida College of Medicine, Tampa, Florida
  2. 2Research Service, James A. Haley Veterans Hospital, Tampa, Florida
  1. Address correspondence and reprint requests to Robert V. Farese, ACOS-151, James A. Haley Veterans Administration Medical Center, 13000 Bruce B. Downs Blvd., Tampa, FL 33612. E-mail: rfarese{at}hsc.med.usf.edu
Diabetes 2003 Aug; 52(8): 1926-1934. https://doi.org/10.2337/diabetes.52.8.1926
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Effects of insulin administration in vivo (A), PIP3 treatment in vitro (B), and acute exercise (C) on PKC-ζ/λ/ι activity in vastus lateralis muscles of control nondiabetic patients and in patients who have IGT or type 2 diabetes. A: Insulin was administered during the clamp procedure. B: PIP3 (10 μmol/l) was added to assays of equal amounts of aPKCs immunoprecipitated from basal/unstimulated muscle lysates of nondiabetic control subjects and patients with IGT/diabetic patients (results of one patient with IGT and five diabetic patients were comparable and therefore combined). C: Nondiabetic and diabetic patients were subjected to 20 min bicycle exercise. Clear bars reflect basal/unstimulated values; shaded bars reflect stimulated values. Values are means ± SE of the number of patients shown in parentheses. P values were determined by ANOVA.

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Effects of insulin administration on IRS-1-dependent PI 3-kinase activity (A), PKB-α enzyme activity (B), and phosphorylation of serine-473 in PKB (C and D) in vastus lateralis muscles of control nondiabetic patients and in patients who have IGT or type 2 diabetes. Insulin was administered during the clamp procedure, and muscle samples were the same as those used in Fig. 1. Clear bars reflect basal/unstimulated values; shaded bars reflect stimulated values. Values are means ± SE of the number of patients shown in parentheses. P values were determined by ANOVA. Note that there was little or no measurable PKB phosphorylation in the absence of insulin treatment, as shown in D (which shows representative immunoblots).

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Western analyses of IRS-1, p85 PI 3-kinase, PDK-1, PKC-ζ, combined PKC-ζ/λ/ι, PKC-λ/ι, PKB-α, and GLUT4 glucose transporters in muscles of nondiabetic control subjects (ND or N), patients with IGT, type 2 diabetic patients (DM or D), and type 2 diabetic patients treated with rosiglitazone (RSGZ). Note that comparisons were made between samples of nondiabetic control subjects versus patients with IGT or diabetic patients, or diabetic patients before and after rosiglitazone (RSGZ) treatment, as analyzed on the same immunoblot (note that there are different degrees of chemiluminescence development on different blots, as it is necessary to make comparisons within the same blot). Top: Representative immunoblot comparisons. Bottom: Bar graphs depicting relative means ± SE values of multiple (the number of patients examined is shown in parentheses) immunoblot analyses of insulin-sensitive signaling factors, with nondiabetic values set at 100%. Asterisks indicate P values, as determined by ANOVA.

  • FIG. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Effects of rosiglitazone (RSGZ) on insulin-stimulated total-body glucose disposal rates (A), and insulin-stimulated activities of IRS-1-dependent PI 3-kinase (B), PKC-ζ/λ/ι (C), and PKB (D) in vastus lateralis muscle during clamp studies in diabetic patients. Values are means ± SE of the number of patient studies, which is shown in parentheses. P values were determined by ANOVA in A and D and by paired t test in B. For comparison, data from untreated nondiabetic control subjects are included in the figure.

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Effects of rosiglitazone (RSGZ) on insulin-stimulated total-body glucose disposal rates (A), and insulin-stimulated activities of IRS-1-dependent PI 3-kinase (B), PKC-ζ/λ/ι (C), and PKB (D) in vastus lateralis muscle during clamp studies in diabetic patients. Shown are findings in individual patients (see Fig. 4 for mean values).

Tables

  • Figures
  • TABLE 1

    Patient characteristics

    Nondiabetic control subjectsSubjects with IGTType 2 Diabetic patients
    Age (years)44 ± 2 (18)43 ± 3 (6)50 ± 3 (10)
    BMI27 ± 1 (18)34 ± 2 (6)32 ± 2 (10)
    P < 0.004P < 0.03
    Fasting plasma glucose (mmol/l)5.1 ± 0.2 (18)6.2 ± 0.1 (6)8.7 ± 1.4 (10)
    P < 0.001
    Serum insulin (pmol)111 ± 16 (17)346 ± 124 (6)235 ± 43 (10)
    P < 0.004P < 0.05
    Serum C-peptide (ng/ml)1.46 ± 0.17 (17)3.63 ± 0.97 (6)2.63 ± 0.34 (10)
    P < 0.001P < 0.03
    HbA1c (%)4.79 ± 0.13 (18)5.42 ± 0.25 (6)7.00 ± 0.71 (10)
    P < 0.0003
    Triglycerides (mg/dl)141 ± 16 (18)209 ± 39 (6)209 ± 36 (10)
    Systolic blood pressure (mmHg)127 ± 3 (18)136 ± 76 (6)139 ± 6 (10)
    Diastolic blood pressure (mmHg)76 ± 2 (18)82 ± 3 (6)85 ± 2 (10)
    P < 0.02
    Serum free fatty acids (mmol)0.44 ± 0.03 (17)0.52 ± 0.08 (4)0.51 ± 0.04 (10)
    Glucose disposal rate (mg · kg−1 · min−1)11.60 ± 1.11 (18)5.92 ± 1.01 (6)4.90 ± 0.74 (10)
    P < 0.004P < 0.0001
    • Data are means ± SE (number of determinations). P values versus normal nondiabetic control subjects, by ANOVA.

PreviousNext
Back to top
Advertisement

In this Issue

August 2003, 52(8)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Activation of Protein Kinase C-ζ by Insulin and Phosphatidylinositol-3,4,5-(PO4)3 Is Defective in Muscle in Type 2 Diabetes and Impaired Glucose Tolerance
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
Citation Tools
Activation of Protein Kinase C-ζ by Insulin and Phosphatidylinositol-3,4,5-(PO4)3 Is Defective in Muscle in Type 2 Diabetes and Impaired Glucose Tolerance
Mary Beeson, Mini P. Sajan, Michelle Dizon, Dmitry Grebenev, Joaquin Gomez-Daspet, Atsushi Miura, Yoshinori Kanoh, Jennifer Powe, Gautam Bandyopadhyay, Mary L. Standaert, Robert V. Farese
Diabetes Aug 2003, 52 (8) 1926-1934; DOI: 10.2337/diabetes.52.8.1926

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Activation of Protein Kinase C-ζ by Insulin and Phosphatidylinositol-3,4,5-(PO4)3 Is Defective in Muscle in Type 2 Diabetes and Impaired Glucose Tolerance
Mary Beeson, Mini P. Sajan, Michelle Dizon, Dmitry Grebenev, Joaquin Gomez-Daspet, Atsushi Miura, Yoshinori Kanoh, Jennifer Powe, Gautam Bandyopadhyay, Mary L. Standaert, Robert V. Farese
Diabetes Aug 2003, 52 (8) 1926-1934; DOI: 10.2337/diabetes.52.8.1926
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PDK4 Augments ER–Mitochondria Contact to Dampen Skeletal Muscle Insulin Signaling During Obesity
  • FoxO Transcription Factors Are Critical Regulators of Diabetes-Related Muscle Atrophy
  • miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity
Show more Signal Transduction

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • For Advertisers
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org
Advertisement

© 2019 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.